NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $22 | $97 | $89 | $3 |
| Gross Profit | -$22 | -$97 | -$89 | -$3 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,698 | $7,274 | $6,416 | $3,082 |
| G&A Expenses | $4,204 | $4,775 | $7,136 | $2,505 |
| SG&A Expenses | $4,204 | $4,775 | $7,136 | $2,505 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$22 | $0 | -$89 | $0 |
| Operating Expenses | $9,880 | $12,049 | $13,463 | $5,587 |
| Operating Income | -$9,902 | -$12,049 | -$13,552 | -$5,587 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$308 | $1,942 | $1,212 | $1,546 |
| Pre-Tax Income | -$10,210 | -$11,280 | -$12,340 | -$4,041 |
| Tax Expense | $0 | $0 | -$1,143 | $0 |
| Net Income | -$10,210 | -$10,107 | -$12,340 | -$4,041 |
| % Margin | – | – | – | – |
| EPS | -0.55 | -0.83 | -1.07 | -0.23 |
| % Growth | 33.7% | 22.4% | -365.2% | – |
| EPS Diluted | -0.55 | -0.83 | -1.07 | -0.23 |
| Weighted Avg Shares Out | 18,602 | 13,640 | 11,505 | 10,856 |
| Weighted Avg Shares Out Dil | 18,602 | 13,640 | 11,505 | 10,856 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $178 | $91 | $0 |
| Interest Expense | $311 | $550 | $15 | $1,154 |
| Depreciation & Amortization | $22 | $21 | $89 | $3 |
| EBITDA | -$9,877 | -$9,638 | -$12,229 | -$2,884 |
| % Margin | – | – | – | – |